|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,664 JPY | +1.87% |
|
+1.93% | +1.15% |
| Apr. 25 | AstraZeneca upbeat as cancer drugs underpin sales growth | AN |
| Apr. 08 | AstraZeneca hails neurological data for Ultomiris, Soliris | AN |
Sankyo Co., Ltd. reported earnings results for the nine months ended December 31, 2023. For the nine months, the company reported sales was JPY 170,588 million compared to JPY 128,065 million a year ago. Net income was JPY 48,244 million compared to JPY 38,670 million a year ago.
Basic earnings per share from continuing operations was JPY 174.426 compared to JPY 133.178 a year ago. Diluted earnings per share from continuing operations was JPY 172.464 compared to JPY 131.746 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +1.15% | 2.32B | |
| +11.20% | 8.25B | |
| +13.39% | 718M | |
| +29.76% | 358M | |
| +5.69% | 349M | |
| +3.88% | 327M | |
| -6.11% | 270M | |
| +15.54% | 182M | |
| +26.63% | 99.29M | |
| -28.33% | 63.25M |
SANKYO CO., LTD. 
